Beranda › Obesitas › Indiana › Evansville
Uji klinis Obesitas di Evansville, IN
5 studi untuk Obesitas mencari peserta di lokasi sekitar Evansville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Menerima pesertaFase 3
- MediSphere Medical Research Center, LLC, Evansville
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Menerima pesertaFase 3
- Qualmedica Research, LLC, Evansville
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Menerima pesertaFase 3
- AURORA-1 Clinical Site, Evansville
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Menerima pesertaFase 3
- AURORA-2 Clinical Site, Evansville
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Menerima pesertaFase 3
- Research Integrity Global, LLC, Owensboro · 28 mi jauhnya
Uji klinis Obesitas di kota lain
- Houston, TX43 studi
- Chicago, IL41 studi
- New York City, NY40 studi
- San Antonio, TX40 studi
- Washington, DC33 studi
- Orlando, FL31 studi
- Dallas, TX30 studi
- Boston, MA28 studi
- Las Vegas, NV27 studi
- Miami, FL27 studi
- Baltimore, MD25 studi
- Jacksonville, FL25 studi
Studi lain di Evansville
- Gagal Jantung6 studi
- Penyakit Kardiovaskular6 studi
- Diabetes Tipe 26 studi
- Asma5 studi
- Kelebihan Berat Badan4 studi
- Kanker Payudara3 studi
- Kanker Paru Non-Sel Kecil3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.